Welcome to our dedicated page for Protalix BioTherapeutics SEC filings (Ticker: PLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protalix BioTherapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with NYSE American-listed common stock and a business built around recombinant therapeutic proteins produced through ProCellEx®. The company’s Form 8-K reports cover operating results, financial condition, business and clinical updates, corporate presentations, stockholder communications and regulatory events involving Elfabrio®.
Protalix’s proxy materials describe board governance, executive compensation, equity awards and shareholder voting matters. Its regulatory disclosures also identify material event reporting around European regulatory actions for Elfabrio, collaboration-related communications with commercialization partners, and the capital-market status of its common stock.
Protalix BioTherapeutics (NYSE:PLX) filed an 8-K disclosing the results of its 2025 Annual Meeting held on June 26, 2025.
- Eight directors elected: top nominee received 22.4 M votes for versus 1.9 M withheld; 12.7 M broker non-votes across the slate.
- Say-on-pay approved: 16.4 M for, 7.5 M against, 0.38 M abstentions, 12.7 M broker non-votes.
- PwC Israel ratified as auditor for FY 2025: 34.9 M for, 1.6 M against, 0.46 M abstentions.
No additional material actions or strategic updates were reported.